Bristol-Myers, Merck Drugs Give Hope in Hodgkin’s Trials

December 7, 2014 5:39 AM

2 0

Drugs by Bristol-Myers Squibb Co. (BMY:US) and Merck & Co. (MRK:US) showed promise in early trial results for treatment of Hodgkin’s lymphoma, potentially expanding the types of cancer they may be able to fight.

The drugs work by blocking a pathway called PD-1 to boost the immune system and battle cancer cells that manage to evade the body’s natural defenses. Merck’s drug, Keytruda, has already been approved by the U.S. Food and Drug Administration to treat melanoma, the deadliest form of skin cancer.

Read more

To category page